A detailed history of Bvf Inc transactions in 89bio, Inc. stock. As of the latest transaction made, Bvf Inc holds 7,568,479 shares of ETNB stock, worth $75.5 Million. This represents 1.85% of its overall portfolio holdings.

Number of Shares
7,568,479
Previous 4,047,354 87.0%
Holding current value
$75.5 Million
Previous $47.1 Million 28.68%
% of portfolio
1.85%
Previous 1.41%

Shares

5 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 14, 2024

BUY
$7.31 - $10.9 $25.7 Million - $38.4 Million
3,521,125 Added 87.0%
7,568,479 $60.6 Million
Q4 2023

Feb 14, 2024

BUY
$6.66 - $16.03 $14.7 Million - $35.3 Million
2,201,200 Added 119.23%
4,047,354 $45.2 Million
Q1 2023

May 15, 2023

BUY
$10.48 - $16.94 $19.3 Million - $31.3 Million
1,846,154 New
1,846,154 $28.1 Million
Q3 2022

Nov 14, 2022

SELL
$3.02 - $7.0 $2.28 Million - $5.28 Million
-754,318 Reduced 19.35%
3,143,682 $18.2 Million
Q2 2022

Aug 15, 2022

BUY
$2.09 - $4.02 $8.15 Million - $15.7 Million
3,898,000 New
3,898,000 $12.6 Million

Others Institutions Holding ETNB

About 89bio, Inc.


  • Ticker ETNB
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 46,484,500
  • Market Cap $463M
  • Description
  • 89bio, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for the treatment of liver and cardio-metabolic diseases. Its lead product candidate is pegozafermin, a glycoPEGylated analog of fibroblast growth factor 21 for the treatment of nonalcoholic steatohepatitis. The company also int...
More about ETNB
Track This Portfolio

Track Bvf Inc Portfolio

Follow Bvf Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Bvf Inc, based on Form 13F filings with the SEC.

News

Stay updated on Bvf Inc with notifications on news.